AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21309806 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for lenses
Number of subjects: 28
Study 19685113 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐gauge catheter (20G)
Number of subjects: 30
Study 19685113 — intervention group
Group type: COMPARATOR
Intervention: 22‐gauge catheter (22G)
Number of subjects: 30
Study 16730541 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy (TWT)
Number of subjects: 150
Study 16730541 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocautery tonsillectomy (BET)
Number of subjects: 150
Study 15584820 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic search method
Number of subjects: 0
Study 15584820 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory search
Number of subjects: 0
Study 15584820 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced memory trials
Number of subjects: 0
Study 15584820 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice between vision and memory
Number of subjects: 0
Study 11376827 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (10-20 mg per day)
Number of subjects: 40
Study 11376827 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50-100 mg per day)
Number of subjects: 40
Study 11376827 — intervention group
Group type: COMPARATOR
Intervention: baseline untreated hypertensive patients
Number of subjects: 40
Study 11376827 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril or losartan
Number of subjects: 40
Study 9401542 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment at a dose of 0.1 IU/kg/day for 2 years (group A)
Number of subjects: 27
Study 9401542 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone treatment at a dose of 0.2 IU/kg/day for the second year (group B)
Number of subjects: 27
Study 9401542 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 27
Study 7811026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure (enteral feeding product)
Number of subjects: 13
Study 7811026 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 13
Study 3417845 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3/day
Number of subjects: 142
Study 3417845 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3/day
Number of subjects: 142
Study 3417845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 142
Study 31634897 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg
Number of subjects: 37
Study 31634897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31618598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 bouts of 5-min counterweighted, single-leg cycling
Number of subjects: 9
Study 31618598 — intervention group
Group type: COMPARATOR
Intervention: 1 bout of 5-min counterweighted, single-leg cycling
Number of subjects: 9
Study 31618598 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 4-bout and 1-bout groups
Number of subjects: 9
Study 28325123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% menthol gel applied to the skin over the quadriceps muscle
Number of subjects: 42
Study 28325123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Adult Placebo group)
Number of subjects: 42
Study 25460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 353
Study 25460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LVESVi
Number of subjects: 353
Study 25460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Other remodeling parameters (left ventricular end-diastolic volume index and ejection fraction)
Number of subjects: 353
Study 23216900 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS‐RIII)
Number of subjects: 135
Study 23216900 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child reports
Number of subjects: 135
Study 23216900 — intervention group
Group type: COMPARATOR
Intervention: QPGS‐RIII
Number of subjects: 135
Study 23216900 — intervention group
Group type: COMPARATOR
Intervention: Diaries
Number of subjects: 135
Study 21249489 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetogenic VPS13C/C2CD4A/C2CD4B rs7172432 A allele
Number of subjects: 5722
Study 18481578 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system
Number of subjects: 60
Study 18481578 — intervention group
Group type: COMPARATOR
Intervention: Self-etch adhesive system
Number of subjects: 60
Study 18481578 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled margins
Number of subjects: 60
Study 16575035 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg iv
Number of subjects: 9
Study 16575035 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL (placebo)
Number of subjects: 9
Study 16575035 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg iv
Number of subjects: 9
Study 14736355 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 29
Study 14736355 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 29
Study 10910857 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (Group B)
Number of subjects: 180
Study 10910857 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% (Group R)
Number of subjects: 180
Study 10910857 — intervention group
Group type: COMPARATOR
Intervention: saline (Group S)
Number of subjects: 180
Study 8959423 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 18
Study 8959423 — intervention group
Group type: COMPARATOR
Intervention: Time Interval Condition (TIC)
Number of subjects: 18
Study 8959423 — intervention group
Group type: COMPARATOR
Intervention: Tapping Alternate Phalanges (TAP)
Number of subjects: 18
Study 1525903 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytics and Mg-lactate
Number of subjects: 20
Study 1525903 — intervention group
Group type: COMPARATOR
Intervention: Anxiolitics and placebo
Number of subjects: 20
Study 3897612 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally before a meal
Number of subjects: 62
Study 3897612 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally after a light meal
Number of subjects: 62
Study 3897612 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg of S6472 given orally after a usual meal
Number of subjects: 62
Study 3897612 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 to 1,500 mg/day of S6472
Number of subjects: 62
Study 3897612 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472
Number of subjects: 62
Study 30244288 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restricted resistance exercise (BFR‐RE)
Number of subjects: 0
Study 30244288 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 26655188 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS on left DLPFC
Number of subjects: 32
Study 26655188 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological agents)
Number of subjects: 32
Study 25461205 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (topiramate)
Number of subjects: 249
Study 25461205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 22353512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fujinon EC‐450 (FS)
Number of subjects: 86
Study 22353512 — intervention group
Group type: COMPARATOR
Intervention: Olympus GIF‐Q260 (OS)
Number of subjects: 86
Study 22353512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FS and OS
Number of subjects: 86
Study 20822286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem inconsistent feedback
Number of subjects: 0
Study 20822286 — intervention group
Group type: EXPERIMENTAL
Intervention: Social feedback (various operationalizations)
Number of subjects: 0
Study 20822286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance signaling system
Number of subjects: 0
Study 20822286 — intervention group
Group type: EXPERIMENTAL
Intervention: Epistemic signaling system
Number of subjects: 0
Study 17362423 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing paraffin wax for 10 minutes after stress loading
Number of subjects: 17
Study 17362423 — intervention group
Group type: EXPERIMENTAL
Intervention: Light clenching for 3 minutes after stress loading
Number of subjects: 17
Study 17362423 — intervention group
Group type: COMPARATOR
Intervention: Control (no chewing)
Number of subjects: 17
Study 17362423 — intervention group
Group type: COMPARATOR
Intervention: Control (rest periods during clenching)
Number of subjects: 17
Study 15752881 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy radiotherapy
Number of subjects: 669
Study 15752881 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy radiotherapy
Number of subjects: 669
Study 15752881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 68 Gy and 78 Gy radiotherapy
Number of subjects: 669
Study 12046005 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles (QCs) among first-year medical students, meeting once a week for 14 sessions of 45 minutes each.
Number of subjects: 135
Study 12046005 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles (QCs) among first-year medical students.
Number of subjects: 135
Study 10456621 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of warfarin (group A)
Number of subjects: 41
Study 10456621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fixed dose of warfarin (1.25 mg/day) for an additional month (group B)
Number of subjects: 41
Study 10456621 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 41
Study 7842190 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmaexpert (expert system)
Number of subjects: 127
Study 7842190 — intervention group
Group type: COMPARATOR
Intervention: Expert opinions
Number of subjects: 127
Study 2404052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose simvastatin
Number of subjects: 20
Study 2404052 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose simvastatin
Number of subjects: 20
Study 2404052 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 to 40 mg)
Number of subjects: 20
Study 856370 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire on chest pain and intermittent claudication
Number of subjects: 18403
Study 856370 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 18403
Study 31007215 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tacrolimus 0.03% ointment
Number of subjects: 90
Study 31007215 — intervention group
Group type: COMPARATOR
Intervention: Topical Dexamethasone 0.05% ointment
Number of subjects: 90
Study 28351204 — intervention group
Group type: EXPERIMENTAL
Intervention: Visi‐Pro Balloon‐Expandable Peripheral Stent System
Number of subjects: 75
Study 25736724 — intervention group
Group type: EXPERIMENTAL
Intervention: NFCT
Number of subjects: 40
Study 23559402 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral dose of olanzapine
Number of subjects: 63
Study 21616195 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured meal‐plan‐based diet and supervised exercise program (SDE)
Number of subjects: 90
Study 21616195 — intervention group
Group type: COMPARATOR
Intervention: Meal‐replacement‐based diet program (MRP)
Number of subjects: 90
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 50 mg t.i.d. (n = 7)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 60 mg t.i.d. (n = 9)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 100 mg t.i.d. (n = 7)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d. (n = 9)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 150 mg t.i.d. (n = 16)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 240 mg t.i.d. (n = 9)
Number of subjects: 99
Study 19220279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 300 mg t.i.d. (n = 9)
Number of subjects: 99
Study 19220279 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120 mg t.i.d. (n = 9)
Number of subjects: 99
Study 17427819 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000 (3M ESPE)
Number of subjects: 33
Study 17427819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP (Dentsply)
Number of subjects: 33
Study 15209321 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal content cues training
Number of subjects: 0
Study 15209321 — intervention group
Group type: COMPARATOR
Intervention: No cue training (Control)
Number of subjects: 0
Study 15209321 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and vocal content cues training
Number of subjects: 0
Study 11561263 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% plus fentanyl 2.5 microg/mL (group BF)
Number of subjects: 60
Study 11561263 — intervention group
Group type: COMPARATOR
Intervention: 40 mL bupivacaine 0.25% (group B)
Number of subjects: 60
Study 11561263 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.125% plus fentanyl 2.5 microg/mL (group DBF)
Number of subjects: 60
Study 9628078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy (CBT)
Number of subjects: 17
Study 7930046 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial expression condition
Number of subjects: 0
Study 7930046 — intervention group
Group type: COMPARATOR
Intervention: Initial suppression condition
Number of subjects: 0
Study 3421199 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte beverage (MC)
Number of subjects: 0
Study 3421199 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (P)
Number of subjects: 0
Study 3421199 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% carbohydrate-electrolyte beverage (LC)
Number of subjects: 0
Study 29703289 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (ocular bandage gel 4 times a day for 14 days and bandage contact lens)
Number of subjects: 39
Study 29703289 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (ocular bandage gel 4 times a day for 14 days)
Number of subjects: 39
Study 29703289 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control; bandage contact lens and artificial tears 4 times a day for 14 days)
Number of subjects: 39
Study 27993177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch diet with lower carbohydrate intake
Number of subjects: 52
Study 27993177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch diet with higher carbohydrate intake
Number of subjects: 52
Study 27993177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch meal with lower carbohydrate intake
Number of subjects: 52
Study 27993177 — intervention group
Group type: COMPARATOR
Intervention: High-resistant starch diet
Number of subjects: 52
Study 24622164 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis resource management instruction (1 hour)
Number of subjects: 15
Study 24622164 — intervention group
Group type: COMPARATOR
Intervention: No additional training (Control)
Number of subjects: 15
Study 23516685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 97
Study 23516685 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 97
Study 23516685 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Biofeedback and Hypnotherapy
Number of subjects: 97
Study 23516685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and Hypnotherapy
Number of subjects: 97
Study 19877267 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm everolimus-eluting stent (EES)
Number of subjects: 69
Study 19877267 — intervention group
Group type: COMPARATOR
Intervention: TAXUS EXPRESS(2) paclitaxel-eluting stent (PES)
Number of subjects: 69
Study 19877267 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm EES
Number of subjects: 69
Study 19877267 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 69
Study 18798783 — intervention group
Group type: EXPERIMENTAL
Intervention: Everest system
Number of subjects: 45
Study 18798783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava system
Number of subjects: 45
Study 18798783 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera system
Number of subjects: 45
Study 18798783 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CAD/CAM systems
Number of subjects: 45
Study 18798783 — intervention group
Group type: COMPARATOR
Intervention: Time phases
Number of subjects: 45
Study 16076697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential, dose-dense epirubicin plus docetaxel
Number of subjects: 34
Study 11920355 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin solution (Extraneal)
Number of subjects: 39
Study 11920355 — intervention group
Group type: COMPARATOR
Intervention: 2.27% glucose solution
Number of subjects: 39
Study 10336842 — intervention group
Group type: EXPERIMENTAL
Intervention: C1165G polymorphism in the beta1-adrenoceptor gene
Number of subjects: 426
Study 10336842 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 426
Study 8529496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (220 micrograms elemental chromium daily for 90 days)
Number of subjects: 26
Study 8529496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1760827 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 120 sustained-release
Number of subjects: 30
Study 1760827 — intervention group
Group type: EXPERIMENTAL
Intervention: combination therapy (ISDN + verapamil)
Number of subjects: 30
Study 1760827 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN retard 120
Number of subjects: 30
Study 7161777 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 to 25 mg oral or intramuscular
Number of subjects: 21
Study 7161777 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 21
Study 31445787 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 42
Study 31445787 — intervention group
Group type: COMPARATOR
Intervention: Open reduction-internal fixation (ORIF)
Number of subjects: 42
Study 29565948 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SR-nitrite, BID
Number of subjects: 24
Study 29565948 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg SR-nitrite, BID
Number of subjects: 24
Study 29565948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25378638 — intervention group
Group type: COMPARATOR
Intervention: Control (Solitaire stentriever plus guide catheter)
Number of subjects: 45
Study 25378638 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus proximal Funnel placement
Number of subjects: 45
Study 25378638 — intervention group
Group type: EXPERIMENTAL
Intervention: Control plus distal Funnel placement
Number of subjects: 45
Study 23347253 — intervention group
Group type: EXPERIMENTAL
Intervention: 1410 nm fractional photothermolysis laser at 20 mJ, 5% coverage
Number of subjects: 30
Study 23347253 — intervention group
Group type: COMPARATOR
Intervention: 1410 nm fractional photothermolysis laser at 20 mJ, 20% coverage
Number of subjects: 30
Study 23347253 — intervention group
Group type: EXPERIMENTAL
Intervention: 1410 nm fractional photothermolysis laser (both sides)
Number of subjects: 30
Study 23161296 — intervention group
Group type: EXPERIMENTAL
Intervention: Information video (n=124)
Number of subjects: 227
Study 23161296 — intervention group
Group type: COMPARATOR
Intervention: Verbal information (n=103)
Number of subjects: 227
Study 20709946 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions
Number of subjects: 29
Study 20709946 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training interventions
Number of subjects: 29
Study 20709946 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic counseling interventions
Number of subjects: 29
Study 20709946 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions (jointly delivered to patients and caregivers)
Number of subjects: 29
Study 17492467 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTG(2)/ATTGT(2) and GG genotypes of NF-kappaB1 and NF-kappaBIalpha
Number of subjects: 185
Study 17492467 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-kappaB1 ATTG(2)/ATTG(2) and NF-kappaBIalpha GG genotypes
Number of subjects: 185
Study 17492467 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTG(1)/ATTG(1) genotype
Number of subjects: 185
Study 17492467 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-kappaBIalpha GG genotype
Number of subjects: 185
Study 17492467 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-kappaBIalpha genotypes
Number of subjects: 185
Study 16834832 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 459
Study 16834832 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (40 mg)
Number of subjects: 459
Study 12595814 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective phosphodiesterase type-5 inhibitors
Number of subjects: 0
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine 0.3 mg/kg
Number of subjects: 20
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg
Number of subjects: 20
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-ketamine 0.5 mg/kg
Number of subjects: 20
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.15 mg/kg
Number of subjects: 20
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-ketamine
Number of subjects: 20
Study 10893703 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine
Number of subjects: 20
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture at altitude (ALT)
Number of subjects: 18
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture at altitude (ALT)
Number of subjects: 18